
Opinion|Videos|September 26, 2024
Closing Remarks
Panelists discuss how their approaches to treating patients with rheumatoid arthritis focus on personalized strategies that prioritize achieving remission while carefully monitoring safety and efficacy outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Can each of you provide closing remarks on how you treat your own patients to achieve remission?
Advertisement
Related to this article

A FIBRONEER-ILD subgroup analysis presented at ACR 2026 found no heterogeneity in nerandomilast's effect on FVC decline or clinical events.

Secukinumab 150 mg doubled week-52 sustained remission vs placebo in REPLENISH, making it the first anti-IL-17 biologic approved for PMR.

Afimetoran achieved SRI-4 response rates of 64.1% to 67.8% vs 34.4% with placebo in a phase 2 SLE trial.

The 200-mg dose improved ACR20 response vs placebo at week 16 in biologic-naïve patients, while the 400-mg dose added no benefit.

An international IgG4ward! Foundation panel issued 28 treatment statements for IgG4-related diseases, with consensus reached on 22.

In 33 patients with myositis-associated ILD from FIBRONEER-ILD, nerandomilast numerically slowed FVC decline and lowered progression risk.

RESET-RA 24-month data show sustained clinical responses with vagus nerve stimulation in patients with treatment-experienced RA.
Advertisement
Advertisement

